TVRD: Tvardi Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
57 institutions reported holding $4.21M of Tvardi Therapeutics, Inc. on Form 13F (67 the quarter before). 12 opened a new position and 20 sold out. Shares held by institutions: -18%.
| Largest holders | Shares | Value |
|---|---|---|
| Slate Path Capital LP | 704,118 | $1.34M |
| VANGUARD CAPITAL MANAGEMENT LLC | 344,382 | $654K |
| AMERICAN FINANCIAL GROUP INC | 223,659 | $425K |
| UBS Group AG | 111,133 | $211K |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 101,034 | $192K |
| BlackRock, Inc. | 95,478 | $181K |
| RENAISSANCE TECHNOLOGIES LLC | 91,409 | $174K |
| GEODE CAPITAL MANAGEMENT, LLC | 90,350 | $172K |
| MORGAN STANLEY | 77,845 | $148K |
| Duncan Williams Asset Management, LLC | 63,241 | $120K |
Clinical trial readouts
1 Phase 2 or 3 trials by Tvardi Therapeutics, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-05-25 (est.) | TTI-101 | Hepatocellular Carcinoma | Phase 1/2 | 193 | Recruiting | NCT05440708 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.